CA
IDXX icon

Crewe Advisors’s Idexx Laboratories IDXX Stock Holding History

Crewe Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16K Buy
6
+5
+500% +$2.8K ﹤0.01% 951
2026
Q1 		$562 Sell
1
-2
-67% -$1.28K ﹤0.01% 987
2025
Q4 		$2.03K Buy
+3
New +$2.04K ﹤0.01% 879
2024
Q4 		– Sell
-38
Closed -$19.2K – 720
2024
Q3 		$19.2K Hold
38
– – ﹤0.01% 411
2024
Q2 		$18.5K Sell
38
-11
-22% -$5.52K ﹤0.01% 566
2024
Q1 		$26.5K Buy
+49
New +$26.8K ﹤0.01% 458
2023
Q1 		– Sell
-10
Closed -$4.08K – 929
2022
Q4 		$4.08K Sell
10
-43
-81% -$16.7K ﹤0.01% 711
2022
Q3 		$17K Buy
53
+6
+13% +$2.2K ﹤0.01% 508
2022
Q2 		$16K Buy
+47
New +$19.2K ﹤0.01% 479
2021
Q3 		– Sell
-1
Closed -$1K – 428
2021
Q2 		$1K Sell
1
-11
-92% -$6.07K ﹤0.01% 438
2021
Q1 		$6K Hold
12
– – ﹤0.01% 347
2020
Q4 		$6K Hold
12
– – ﹤0.01% 330
2020
Q3 		$5K Buy
+12
New +$4.44K ﹤0.01% 353

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Crewe Advisors's IDXX Position: Q2 2026 in Review

Crewe Advisors increased its Idexx Laboratories (IDXX) stake by 500% in Q2 2026, buying an estimated $2.8K and bringing the position to 6 shares worth $3.16K. The position accounts for ﹤0.01% of the portfolio, ranked #951.

Crewe Advisors first reported a position in IDXX in Q3 2020 and has held it in 13 quarters since. The position peaked at $26.5K in Q1 2024. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Crewe Advisors held 6 shares of Idexx Laboratories worth $3.16K as of Q2 2026.
  • Crewe Advisors bought 5 Idexx Laboratories shares in Q2 2026, an estimated $2.8K.
  • Idexx Laboratories made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #951 holding.
  • Crewe Advisors first reported a position in Idexx Laboratories in Q3 2020 and has held it in 13 quarters since.
  • Crewe Advisors's Idexx Laboratories position peaked at $26.5K in Q1 2024.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.